Ephedrine (DrugBank: Ephedrine)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-001355-23-NL (EUCTR) | 29/08/2014 | 14/05/2014 | Ephedrine as add-on therapy for patients with myasthenia gravis | Ephedrine as add-on therapy for patients with myasthenia gravis - Ephedrine for MG | myasthenia gravis MedDRA version: 17.0;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Hidrocloruro de efedrina INN or Proposed INN: EPHEDRINE HYDROCHLORIDE Other descriptive name: EPHEDRINE HYDROCHLORIDE | Leiden University Medical Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 2 | NCT00541216 (ClinicalTrials.gov) | October 2007 | 7/10/2007 | Ephedrine for the Treatment of Congenital Myasthenia | Myasthenic Syndromes, Congenital | Drug: Ephedrine | Hadassah Medical Organization | NULL | Enrolling by invitation | 12 Years | 75 Years | Both | 15 | Phase 1;Phase 2 | Israel |